- Home
- ANTX vs RPTX Comparison
ANTX vs RPTX Comparison
Compare ANTX & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- RPTX
- Stock Information
- Founded
- ANTX 2017
- RPTX 2016
- Country
- ANTX United States
- RPTX Canada
- Employees
- ANTX 36
- RPTX 129
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- RPTX Health Care
- Exchange
- ANTX Nasdaq
- RPTX Nasdaq
- Market Cap
- ANTX 38.5M
- RPTX 38.3M
- IPO Year
- ANTX 2022
- RPTX 2020
- Fundamental
- Price
- ANTX $1.26
- RPTX $1.20
- Analyst Decision
- ANTX Buy
- RPTX Strong Buy
- Analyst Count
- ANTX 4
- RPTX 3
- Target Price
- ANTX $3.50
- RPTX $4.50
- AVG Volume (30 Days)
- ANTX 79.8K
- RPTX 448.7K
- Earning Date
- ANTX 05-13-2025
- RPTX 05-06-2025
- Dividend Yield
- ANTX N/A
- RPTX N/A
- EPS Growth
- ANTX N/A
- RPTX N/A
- EPS
- ANTX N/A
- RPTX N/A
- Revenue
- ANTX N/A
- RPTX $53,477,000.00
- Revenue This Year
- ANTX N/A
- RPTX N/A
- Revenue Next Year
- ANTX N/A
- RPTX $7.14
- P/E Ratio
- ANTX N/A
- RPTX N/A
- Revenue Growth
- ANTX N/A
- RPTX 4.58
- 52 Week Low
- ANTX $0.87
- RPTX $0.89
- 52 Week High
- ANTX $3.07
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- ANTX 44.61
- RPTX 62.88
- Support Level
- ANTX $1.18
- RPTX $0.89
- Resistance Level
- ANTX $1.33
- RPTX $1.02
- Average True Range (ATR)
- ANTX 0.09
- RPTX 0.08
- MACD
- ANTX -0.01
- RPTX 0.03
- Stochastic Oscillator
- ANTX 42.86
- RPTX 72.09
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.